Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Compass Therapeutics (NASDAQ:CMPX) posted its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), FiscalAI reports.

Compass Therapeutics Trading Up 8.0%

Shares of CMPX stock traded up $0.16 during mid-day trading on Friday, reaching $2.15. The stock had a trading volume of 3,825,555 shares, compared to its average volume of 2,660,902. Compass Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.88. The firm has a market cap of $387.19 million, a price-to-earnings ratio of -5.37 and a beta of 0.92. The business’s fifty day moving average is $2.09 and its 200-day moving average is $3.86.

Compass Therapeutics News Roundup

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target on Compass Therapeutics from $4 to $6 and upgraded its outlook to “overweight,” implying substantial potential upside from recent trading levels. Benzinga article
• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $24 price target, signaling significant long-term upside if the company’s development programs progress successfully. The firm also modestly improved its FY2028 EPS forecast to a loss of $0.56 per share from a loss of $0.58.
• Neutral Sentiment: Analyst opinion is highly divided: Wall Street Zen reportedly downgraded Compass Therapeutics to “Strong Sell,” contrasting sharply with the Buy and Overweight ratings from HC Wainwright and Piper Sandler. Compass Therapeutics rating article
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q3 2026 to a loss of $0.15 from $0.11, Q4 2026 to a loss of $0.17 from $0.12, and full-year 2026 to a loss of $0.55 from $0.45. Its FY2027 forecast also declined slightly to a loss of $0.56 from $0.55.

Analyst Ratings Changes

A number of research firms have commented on CMPX. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Compass Therapeutics in a research note on Monday, April 27th. Wall Street Zen downgraded shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. Canaccord Genuity Group dropped their target price on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, April 28th. Finally, Citizens Jmp restated a “market outperform” rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.77.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares during the last quarter. Creative Planning acquired a new stake in shares of Compass Therapeutics in the second quarter worth $30,000. Strs Ohio acquired a new stake in shares of Compass Therapeutics in the first quarter worth $34,000. CIBC Bancorp USA Inc. purchased a new position in shares of Compass Therapeutics during the third quarter worth $37,000. Finally, Virtu Financial LLC purchased a new position in shares of Compass Therapeutics during the third quarter worth $44,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.